Structure Therapeutics Inc.
GPCR
$54.38
-$0.32-0.59%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
3/16/2026
-
MarketBeat
8/13/2026
-
Zacks Investment Research
8/13/2026
-
Zacks Investment Research
8/12/2026
-
Zacks Investment Research
8/12/2026
-
The Cerbat Gem
8/11/2026
-
MarketBeat
8/11/2026
-
The Cerbat Gem
Structure Therapeutics (GPCR) Names New Commercial Chief, Is The Valuation Upside Already Priced In?
8/10/2026
-
Simply Wall St
8/10/2026
-
TipRanks
8/10/2026
-
ETF Channel
8/10/2026
-
TipRanks
8/10/2026
-
MarketBeat
8/9/2026
-
MarketBeat
8/9/2026
-
MarketBeat
8/8/2026
-
Simply Wall St
8/7/2026
-
MarketBeat
8/7/2026
-
TipRanks
8/7/2026
-
TipRanks
8/7/2026
-
MarketBeat
8/7/2026
-
TipRanks: TheFly
8/7/2026
-
TipRanks: TheFly
8/6/2026
-
Seeking Alpha - Healthcare
8/6/2026
-
Globe Newswire
8/4/2026
-
Tickeron - Stocks
8/4/2026
-
The Cerbat Gem
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Thursday, August 6, 2026
Period Date
Tuesday, June 30, 2026
Next Filing
Week of Nov 2 and 6 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
--
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
--
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
650 457 1978
Address
601 Gateway Boulevard
Suite 900
South San Francisco, CA 94080
Suite 900
South San Francisco, CA 94080
Country
Year Founded
Business Description
Sector
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical...
more